Pharmaceutical

LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia

Submission of NDA for LNZ100 in China by CORXEL Pharmaceuticals results in achievement of first milestone due to LENZ under…

5 months ago

Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

Session Topic is the Innovation and Current Directions in Military Suicide Prevention, Research, and ProgramsPresentation Title is Quantitate Differences in…

5 months ago

Radiopharm Theranostics Receives IND approval from US FDA to Initiate Phase I Therapeutic Clinical Study to target B7H3 with Betabart (RV-01)

Lu177-B7H3 monoclonal antibody is first in class targeted radiopharmaceutical in development against the 4lg subtype of B7-H3 On track to…

5 months ago

HealthLynked Launches New Enterprise Healthcare Solutions Website and Upgraded Provider Directory to Expand Strategic Value Across the Healthcare Market

NAPLES, Fla., July 28, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK), a pioneer in healthcare technology…

5 months ago

Liminatus Pharma Inc. to Launch “American BNB Strategy” Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative

Liminatus Identifies BNB Coin as Its Primary Strategic Target for Digital Asset Allocation, with Plans to Aggressively Accumulate and Hold…

5 months ago

Bio Usawa Biotechnology (Bio Usawa) Partners with DEK Vaccines Ltd (DEK) to Expand Access to Life-Saving Biopharmaceuticals Across Ghana and West Africa

Strategic Distribution Agreement Aims to Address Africa's Growing Non-Communicable Disease Burden with Affordable, World-Class TherapiesKIGALI, Rwanda and SAN FRANCISCO and…

5 months ago

Syndax to Announce Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 4, 2025

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies,…

5 months ago

PharmAla Issues Q3 Financial Statements

TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a…

5 months ago

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active treatment arms compared to placebo,…

5 months ago

POP BIO and CEPI announce collaboration for faster responses to Disease X

Buffalo, NY, July 25, 2025 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a biotechnology company specializing in nanoparticle-based vaccines, and…

5 months ago